Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.76 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | HSD17B14 | Q9BPX1 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003430 | 0.87 | HDAC1 (0.79) | HDAC1SELLSELPHSD17B14KDM4E | |
| SCHEMBL18993050 | 0.87 | HDAC1 (0.62) | HDAC1SELLSELPHSD17B14KDM4E | |
| Exifone SCHEMBL273096 | 0.86 | HDAC1 (1.00) | HDAC1SELLSELPKDM4EALDH1A1 | |
| Exifone SCHEMBL29375026 | 0.86 | HDAC1 (1.00) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL30669853 | 0.86 | HDAC1 (0.84) | HDAC1SELLSELPHSD17B14KDM4E | |
| SCHEMBL6847401 | 0.86 | HDAC1 (0.84) | HDAC1SELLSELPHSD17B14KDM4E | |
| Exifone SCHEMBL27795679 | 0.85 | HDAC1 (0.96) | HDAC1SELLSELPHSD17B14KDM4E | |
| SCHEMBL19763340 | 0.81 | HDAC1 (0.76) | HDAC1SELLSELPHSD17B14KDM4E | |
| SCHEMBL19003424 | 0.81 | HDAC1 (0.70) | HDAC1SELLSELPHSD17B14KDM4E | |
| SCHEMBL18993006 | 0.81 | HDAC1 (0.70) | HDAC1SELLSELPHSD17B14KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2017106861-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639325-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885SELL 4882/4885SELP 4697/4885 |
| US-11180438-B2 | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885SELL 4882/4885SELP 4697/4885 |
| US-20200087236-A9 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885SELL 4882/4885SELP 4697/4885 |
| US-20210171429-A1 | COMPOSITIONS OF POLYHYDROXYLATED BENZOPHENONES AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISORDERS | HDAC1, HDAC10, HDAC6 | HDAC1 1/4885SELL 4882/4885SELP 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.